Bio-Techne Shareholders Approve Merck KGaA Takeover

Bio-Techne Corp. (TECH) shareholders voted on September 23, 2026, to approve the company's acquisition by Germany's Merck KGaA (MKKGY.PK), clearing a key condition for the deal. The approval marks a milestone toward closing the transaction, which remains subject to regulatory clearances and customary closing conditions, the company said. Financial terms and an expected completion date were not disclosed in the announcement. Bio-Techne is a Nasdaq-listed life sciences supplier, while Darmstadt-based Merck KGaA is a diversified pharmaceuticals and specialty chemicals group. The tie-up would fold Bio-Techne's research tools business into Merck's life science portfolio.